FK 506--an effective immunosuppressant in achieving long-term functional islet allograft survival in diabetic rats.

Effect of FK 506 on glucose metabolism and insulin secretion in normal rats.

FK 506 is a powerful immunosuppressant currently being investigated in clinical transplantation. I In vivo administration of this drug resulted in the prolongation of skin, liver, kidney, and heart allografts in large and small animal models.2•3 The immunosuppressive effect has also been shown recently to be effective in the prevention of development of diabetes in BB rats.4 In baboons. treatme...

Long-term survival of islet allografts in diabetic rats treated with FK 506.

FK 506: an effective immunosuppressant for islet xenotransplantation.

R EPLACING the damaged insulin-producing tissue by transplantation of pancreatic islets is considered the most physiological approach to diabetes treatment and has the potential to prevent the development of chronic complications. Due to the large number of potential diabetic recipients. it would be impossible to obtain sufficient supply of donor organs to fulfill the demands. One solution to r...

Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications.

WITH the use of Cy A for clinical liver transplantation, I-year survival rates have approached 70%. Nevertheless, allograft rejection continues to be the most common cause of retransplantation and death. Clinical rejection occurs in 70% ofliver allograft recipients on CyA and steroid therapy. 1 In addition, nephrotoxicity is the principal and dose-limiting side effect of Cy A. Chronic renal dam...

Human islet allotransplantation in 18 diabetic patients.

Nineteen mtrahepatic islet allografts were performed in 18 patients. In group I. nine patients aged 8 to 58 years underwent (ombined liver-Islet allotransplantation following upper-abdominal exenteration for tumors too extensive to be removed with less drastic procedures.b•7 Preliminary results on these patients have been reponed previously.~ In group 2. three type I diabetic patients aged 22 t...